HomeCompareEIGR vs QYLD

EIGR vs QYLD: Dividend Comparison 2026

EIGR yields 115.94% · QYLD yields 12.24%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EIGR wins by $7.30M in total portfolio value
10 years
EIGR
EIGR
● Live price
115.94%
Share price
$1.73
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.32M
Annual income
$2,715,715.87
Full EIGR calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
12.24%
Share price
$16.70
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$6,038.84
Full QYLD calculator →

Portfolio growth — EIGR vs QYLD

📍 EIGR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEIGRQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EIGR + QYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EIGR pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EIGR
Annual income on $10K today (after 15% tax)
$9,855.07/yr
After 10yr DRIP, annual income (after tax)
$2,308,358.49/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,040.82/yr
After 10yr DRIP, annual income (after tax)
$5,133.01/yr
At 15% tax rate, EIGR beats the other by $2,303,225.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EIGR + QYLD for your $10,000?

EIGR: 50%QYLD: 50%
100% QYLD50/50100% EIGR
Portfolio after 10yr
$3.67M
Annual income
$1,360,877.36/yr
Blended yield
37.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EIGR right now

EIGR
Analyst Ratings
11
Buy
Consensus: Buy
Altman Z
-24.5
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EIGR buys
0
QYLD buys
0
No recent congressional trades found for EIGR or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEIGRQYLD
Forward yield115.94%12.24%
Annual dividend / share$2.00$2.04
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$7.32M$26.5K
Annual income after 10y$2,715,715.87$6,038.84
Total dividends collected$6.64M$28.5K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: EIGR vs QYLD ($10,000, DRIP)

YearEIGR PortfolioEIGR Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$22,294$11,594.20$10,384$1,224.49+$11.9KEIGR
2$48,012$24,157.34$10,900$1,388.18+$37.1KEIGR
3$99,994$48,621.05$11,576$1,590.76+$88.4KEIGR
4$201,631$94,637.59$12,447$1,844.20+$189.2KEIGR
5$394,091$178,346.07$13,567$2,164.97+$380.5KEIGR
6$747,454$325,775.96$15,003$2,576.05+$732.5KEIGR
7$1,377,237$577,460.92$16,853$3,110.04+$1.36MEIGR
8$2,468,047$994,404.26$19,251$3,813.85+$2.45MEIGR
9$4,306,232$1,665,421.46$22,390$4,756.08+$4.28MEIGR
10$7,323,384$2,715,715.87$26,548$6,038.84+$7.30MEIGR

EIGR vs QYLD: Complete Analysis 2026

EIGRStock

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Full EIGR Calculator →

QYLDETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this EIGR vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EIGR vs SCHDEIGR vs JEPIEIGR vs OEIGR vs KOEIGR vs MAINEIGR vs XYLDEIGR vs JEPQEIGR vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.